Retraction: Efficacy of dual-functional liposomes containing paclitaxel for treatment of lung cancer (Oncology Reports (2015) 33 (783-791) DOI: 10.3892/or.2014.3644);Efficacy of dual-functional liposomes containing paclitaxel for treatment of lung cancer

Oncology Reports

Volumn 33, Issue 2, 2015, Pages 783-791

  Wang, Rong Hua ^a   Cao, Hong Mei ^a   Tian, Zhi Ju ^a   Jin, Bo ^a   Wang, Qing ^a   Ma, Hong ^a   Wu, Jing ^b  

^a People's Hospital of Zhangqiu   (China)

^b THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

Author keywords

Cell penetrating peptide; Dual ligand; Liposome; Transferrin receptor

Indexed keywords

CELL PENETRATING PEPTIDE; LIPOSOME; MACROGOL; PACLITAXEL; PEPTIDE; PHOSPHOLIPID; T7 PEPTIDE; UNCLASSIFIED DRUG; MACROGOL DERIVATIVE;

A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG RELEASE; DRUG STABILITY; DRUG TARGETING; ENCAPSULATION; ENDOCYTOSIS; IC50; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LUNG CANCER; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; TUMOR SPHEROID; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG SCREENING; HUMAN; LUNG NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; PACLITAXEL; PARTICLE SIZE; POLYETHYLENE GLYCOLS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919458795     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2017.6006     Document Type: Erratum

References (39)

1. Jinturkar KA, Anish C, Kumar MK, Bagchi T, Panda AK and Misra AR: Liposomal formulations of etoposide and docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines. Biomaterials 33: 2492-2507, 2012.
2. Sengupta S, Tyagi P, Velpandian T, et al: Etoposide encapsulated in positively charged liposomes: pharmacokinetic studies in mice and formulation stability studies. Pharmacol Res 42: 459-464, 2000.
3. Maeda H: Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J Control Release 164: 138-144, 2012.
4. Tang J, Zhang L, Liu Y, et al: Synergistic targeted delivery of payload into tumor cells by dual-ligand liposomes co-modifed with cholesterol anchored transferrin and TAT. Int J Pharm 454: 31-40, 2013.
5. Shmeeda H, Amitay Y, Gorin J, et al: Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells. J Control Release 146: 76-83, 2010.
6. Zhang Q, Tang J, Fu L, et al: A pH-responsive α-helical cell penetrating peptide-mediated liposomal delivery system. Biomaterials 34: 7980-7993, 2013.
7. Jiang X, Xin H, Gu J, et al: Solid tumor penetration by integrin-mediated pegylated poly(trimethylene carboNate) nanoparticles loaded with paclitaxel. Biomaterials 34: 1739-1746, 2013.
8. Han L, Huang R, Liu S, et al: Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overex-pressed tumors. Mol Pharm 7: 2156-2165, 2010.
9. Mei D, Gao H, Gong W, et al: Anti glioma effect of doxorubicin loaded liposomes modified with angiopep-2. Afr J Pharm Pharmacol 5: 409-414, 2011.
10. Gao H, Qian J, Yang Z, et al: Whole-cell SELEX aptamer-functionalised poly(ethyleneglycol)-poly(ε-caprolactone) nanoparticles for enhanced targeted glioblastoma therapy. Biomaterials 33: 6264-6272, 2012.
11. Zhang L, Chan JM, Gu FX, et al: Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2: 1696-1702, 2008.
12. + breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is infuenced by antibody binding site and conjugation to polymeric nanoparticles. J Control Release 172: 395-404, 2013.
13. Rossiello R, Carriero MV and Giordano GG: Distribution of ferritin, transferrin and lactoferrin in breast carcinoma tissue. J Clin Pathol 37: 51-55, 1984.
14. Shindelman JE, Ortmeyer AE and Sussman HH: Demonstration of the transferrin receptor in human breast cancer tissue. Potential marker for identifying dividing cells. Int J Cancer 27: 329-334, 1981.
15. Han L, Li J, Huang S, et al: Peptide-conjugated polyamidoamine dendrimer as a nanoscale tumor-targeted T1 magnetic resonance imaging contrast agent. Biomaterials 32: 2989-2998, 2011.
16. Lee JH, Engler JA, Collawn JF and Moore BA: Receptor mediated uptake of peptides that bind the human transferrin receptor. Eur J Biochem 268: 2004-2012, 2001.
17. Oh S, Kim BJ, Singh N P, et al: Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide. Cancer Lett 274: 33-39, 2009.
18. Sharma G, Modgil A, Sun C, Singh J, et al: Grafting of cell-penetrating peptide to receptor-targeted liposomes improves their transfection effciency and transport across Blood-brain barrier model. J Pharm Sci 101: 2468-2478, 2012.
19. Kibria G, Hatakeyama H, Ohga N, et al: Dual-ligand modifcation of PEGylated liposomes shows better cell selectivity and effcient gene delivery. J Control Release 153: 141-148, 2011.
20. Qin Y, Chen H, Zhang Q, et al: Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic effcacy on brain glioma in animals. Int J Pharm 420: 304-312, 2011.
21. Gupta B, Levchenko TS and Torchilin VP: Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev 57: 637-651, 2005.
22. Banks WA, Robinson SM, Nath A, et al: Permeability of the Blood-brain barrier to HIV-1 Tat. Exp Neurol 193: 218-227, 2005.
23. Brooks H, Lebleu B and Vivès E: Tat peptide-mediated cellular delivery: back to basics. Adv Drug Deliv Rev 57: 559-577, 2005.
24. Torchilin VP, Rammohan R, Weissig V and Levchenko TS: TAT peptide on the surface of liposomes affords their effcient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Nat Acad Sci USA 98: 8786-8791, 2001.
25. Allen TM, Brandeis E, Hansen CB, et al: A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in effcient targeting to cancer cells. Biochim Biophys Acta 1237: 99-108, 1995.
26. Du S, Pan H, Lu W, et al: Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fbrosis in rats. J Pharmacol Exp Ther 322: 560-568, 2007.
27. Li F, Sun J, Wang J, et al: Effect of hepatocyte Growth factor encapsulated in targeted liposomes on liver cirrhosis. J Control Release 131: 77-82, 2008.
28. Gao LY, Liu XY, Chen CJ, et al: Core-shell type lipid/rPAA-Chol polymer hybrid nanoparticles for in vivo siRNA delivery. Biomaterials 35: 2066-2078, 2014.
29. McNeeley KM, Karathanasis E, Annapragada AV, Bellamkonda RV: Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors. Biomaterials 30: 3986-3995, 2009.
30. Kuai R, Yuan W, Qin Y, et al: Effcient delivery of payload into tumor cells in a controlled manner by TAT and thiolytic cleavable PEG co-modifed liposomes. Mol Pharm 7: 1816-1826, 2010.
31. Jiang T, Zhang Z, Zhang Y, et al: Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. Biomaterials 33: 9246-9258, 2012.
32. Maeda N, Takeuchi Y, Takada M, et al: Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome. J Control Release 100: 41-52, 2004.
33. Yang T, Choi MK, Cui FD, Kim JS, et al: Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Release 120: 169-177, 2007.
34. Liu Y, Li K, Pan J, et al: Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel. Biomaterials 31: 330-338, 2010.
35. Lewis CE and Pollard JW: Distinct role of macrophages in different tumor microenvironments. Cancer Res 66: 605-612, 2006.
36. Fukumura D, Xu L, Chen Y, Gohongi T, Seed B and Jain RK: Hypoxia and acidosis independently up-regulate vascular endothelial Growth factor transcription in brain tumors in vivo. Cancer Res 61: 6020-6024, 2001.
37. Jain RK: Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 46: 149-168, 2001.
38. Kobayashi H, Man S, Graham CH, et al: Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci USA 90: 3294-3298, 1993.
39. Du J, Lu WL, Ying X, et al: Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the Blood-brain barrier and survival of brain tumor-bearing animals. Mol Pharm 6: 905-917, 2009.